Literature DB >> 26850483

What Happens When Imatinib Goes Generic?

Jean McDougall, Scott D Ramsey, Jerald Radich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26850483     DOI： 10.6004/jnccn.2016.0016

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  2 in total

Review 1.  Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.

Authors:  Verena S Hoffmann; Joerg Hasford; Michael Deininger; Jorge Cortes; Michele Baccarani; Rüdiger Hehlmann
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-08       Impact factor: 4.553

2.  BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report.

Authors:  Ana P Azevedo; Alice Reichert; Celina Afonso; Maria D Alberca; Purificação Tavares; Fernando Lima
Journal:  Clin Med Insights Oncol       Date:  2017-04-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.